(BCACU) – Company Press Releases
-
Apexigen to Participate in the Brookline Capital Markets Newport Symposium
-
Apexigen Appoints William Duke as Chief Financial Officer
-
Apexigen Announces Nature Medicine Publication and ASCO Presentation on the Phase 2 PRINCE Trial Showcasing Distinct Biosignatures in Metastatic Pancreatic Cancer Patients Treated with Sotigalimab and
-
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Mount Rainier Acquisition Corp. (Nasdaq - RNER), Brookline Capital Acquisition Corp. (Nasdaq - BCAC), Vicke
-
Apexigen and Brookline Capital Acquisition Corp. Announce Business Combination Agreement to Create Publicly Listed Immuno-oncology Company
-
Brookline Capital Acquisition Corp. Announces the Separate Trading of its Common Stock and Warrants, Commencing February 22, 2021
-
Brookline Capital Acquisition Corp. Announces the Separate Trading of its Common Stock and Warrants, Commencing February 22, 2021
-
Brookline Capital Acquisition Corp. Completes Closing of $57,500,000 Initial Public Offering
-
Brookline Capital Acquisition Corp. Completes Closing of $57,500,000 Initial Public Offering
-
Brookline Capital Acquisition Corp. Announces Pricing of $50,000,000 Initial Public Offering
-
Bison Capital Acquisition Corp. Announces the Postponement of the Meeting Date for the Special Meeting of Shareholders to Approve Business Combination with Xynomic Pharmaceuticals, Inc.
-
Bison Capital Acquisition Corp. Announces Record and Meeting Dates for the Special Meeting of Shareholders to Approve Business Combination with Xynomic Pharmaceuticals, Inc.
-
Xynomic Pharmaceuticals, Inc. Will Present at ASCO 2019 Annual Meeting, Will Sponsor an EU Investigator Meeting for Potentially Pivotal Kidney Cancer Trial, and Appoints Interim Chief Accounting Offic
-
Xynomic Pharma Achieves Important Regulatory Milestones in China and EU in Potentially Pivotal Kidney Cancer and Lymphoma Trials
-
Xynomic Pharma Doses First South Korean Patient in Phase 3 Renal Cell Carcinoma Trial and Hires Senior Executive Dr. Sophia Paspal to Head Regulatory Affairs and Quality Assurance
-
Bison Capital Acquisition Corp. Clarifies Information of Its Chairman and President
-
Bison Capital Acquisition Corp. and Xynomic Pharmaceuticals, Inc. Announce Signing of Definitive Merger Agreement
-
Bison Capital Acquisition Corp. Ordinary Shares, Warrants and Rights to Commence Trading Separately on or About July 17, 2017
-
Bison Capital Acquisition Corp. Announces Consummation of Over-Allotment Exercise in Connection With Its Initial Public Offering
-
Bison Capital Acquisition Corp. Completes $52,500,000 Initial Public Offering
-
Bison Capital Acquisition Corp. Announces Pricing of $52.5 Million Initial Public Offering
Back to BCACU Stock Lookup
